How many insider trades does FilingIQ track for RVPH?

FilingIQ tracks 13 Form 4 insider transactions for RVPH (REVIVA PHARMACEUTICALS HOLDINGS, INC.), covering filings from Dec 14, 2020 onwards. 3 of those were filed in the last 90 days.

Are RVPH insiders net buyers or net sellers?

Across the full Form 4 history for RVPH, 5 transactions (38%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RVPH insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RVPH in?

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.70M.

RVPH insider trading

NasdaqCM Healthcare

REVIVA PHARMACEUTICALS HOLDINGS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

38% / 0%

Market cap

$4.70M

About REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Company website: www.revivapharma.com

RVPH insider activity at a glance

FilingIQ has scored 13 insider transactions for RVPH since Dec 14, 2020. The most recent filing in our index is dated Mar 18, 2026.

Across the full history, 5 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RVPH insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RVPH trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for RVPH?: FilingIQ tracks 13 Form 4 insider transactions for RVPH (REVIVA PHARMACEUTICALS HOLDINGS, INC.), covering filings from Dec 14, 2020 onwards. 3 of those were filed in the last 90 days.
Are RVPH insiders net buyers or net sellers?: Across the full Form 4 history for RVPH, 5 transactions (38%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RVPH insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RVPH in?: REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.70M.

Methodology & sources

Every RVPH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.